ADCT
ADC Therapeutics SA
NYSE · Healthcare · Biotechnology · CH
$1.05
−0.94%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 1.59x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -0.59x
- Price / sales
- 1.70x
- Price / cash flow
- -1.31x
Enterprise value
- Enterprise value
- $332.1M
- EV / sales
- 4.22x
- EV / EBITDA
- -3.80x
- EV / EBIT
- -3.35x
- Market cap
- $134.1M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026